AJOB neuroscience
January 1, 2023
Andrew Peterson, Emily A Largent, Holly Fernandez Lynch et al.
42 citations
Psychedelic drugs are not currently offered to people with Alzheimer's disease and related dementias, but interest is growing in using them to treat underlying causes and psychiatric symptoms. This paper proposes a research agenda for examining the ethics of psychedelic medicine and research involving persons with AD/ADRD. It offers preliminary analyses of six ethical issues: the impact of psychedelics on autonomy and consent; the effect of "ego dissolution" on those experiencing a pathology of self; how psychedelics might affect caregiving; the potential exploitation of patient desperation; institutional review boards' orientation to psychedelic research; and methods to reduce inequity. These issues are magnified for AD/ADRD but also relevant to other clinical populations.
American Journal of Bioethics
May 2, 2024
Edward Jacobs, B. Earp, Paul S. Appelbaum et al.
29 citations
A workshop on psychedelic ethics, the first Hopkins-Oxford Psychedelic Ethics (HOPE) meeting, was held in August 2023 at the University of Oxford to address ethical issues surrounding psychedelics. The organizers (BDE, DBY, EJ) aimed to foster interdisciplinary discussion on topics such as informed consent, therapeutic use, and societal implications. The report outlines the workshop's structure, key themes, and proposed guidelines for ethical research and practice in the field.
Science
April 27, 2023
Amy L. Mcguire, Holly Fernandez Lynch, Lewis A. Grossman et al.
20 citations
Policy should facilitate the production of evidence regarding the safety and effectiveness of interventions.
The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
January 1, 2026
Holly Fernandez Lynch, Xinping Hu, Alison Bateman-House
2 citations
Psychedelic medicines show potential for treating serious mental health conditions, creating demand before FDA approval. Policymakers should balance evidence, patient safety, and speed by increasing research support, avoiding barriers to research, improving FDA's pre-approval access, and preventing politically driven approvals.